Oncolytic virus and PD-1/PD-L1 blockade combination therapy.

IF 6.7
Oncolytic Virotherapy Pub Date : 2018-07-31 eCollection Date: 2018-01-01 DOI:10.2147/OV.S145532
Chun-Yu Chen, Brian Hutzen, Mary F Wedekind, Timothy P Cripe
{"title":"Oncolytic virus and PD-1/PD-L1 blockade combination therapy.","authors":"Chun-Yu Chen,&nbsp;Brian Hutzen,&nbsp;Mary F Wedekind,&nbsp;Timothy P Cripe","doi":"10.2147/OV.S145532","DOIUrl":null,"url":null,"abstract":"<p><p>Oncolytic viruses are lytic for many types of cancers but are attenuated or replication-defective in normal tissues. Aside from tumor lysis, oncolytic viruses can induce host immune responses against cancer cells and may thus be viewed as a form of immunotherapy. Although recent successes with checkpoint inhibitors have shown that enhancing antitumor immunity can be effective, the dynamic nature of the immunosuppressive tumor microenvironment presents significant hurdles to the broader application of these therapies. Targeting one immune-suppressive pathway may not be sufficient to eliminate tumors. Here we focus on the development of the combination of oncolytic virotherapy with checkpoint inhibitors designed to target the programmed cell death protein 1 and programmed cell death ligand 1 signaling axis. We also discuss future directions for the clinical application of this novel combination therapy.</p>","PeriodicalId":19491,"journal":{"name":"Oncolytic Virotherapy","volume":"7 ","pages":"65-77"},"PeriodicalIF":6.7000,"publicationDate":"2018-07-31","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://sci-hub-pdf.com/10.2147/OV.S145532","citationCount":"56","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Oncolytic Virotherapy","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.2147/OV.S145532","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"2018/1/1 0:00:00","PubModel":"eCollection","JCR":"","JCRName":"","Score":null,"Total":0}
引用次数: 56

Abstract

Oncolytic viruses are lytic for many types of cancers but are attenuated or replication-defective in normal tissues. Aside from tumor lysis, oncolytic viruses can induce host immune responses against cancer cells and may thus be viewed as a form of immunotherapy. Although recent successes with checkpoint inhibitors have shown that enhancing antitumor immunity can be effective, the dynamic nature of the immunosuppressive tumor microenvironment presents significant hurdles to the broader application of these therapies. Targeting one immune-suppressive pathway may not be sufficient to eliminate tumors. Here we focus on the development of the combination of oncolytic virotherapy with checkpoint inhibitors designed to target the programmed cell death protein 1 and programmed cell death ligand 1 signaling axis. We also discuss future directions for the clinical application of this novel combination therapy.

Abstract Image

溶瘤病毒与PD-1/PD-L1阻断剂联合治疗。
溶瘤病毒对许多类型的癌症具有溶解性,但在正常组织中是弱毒的或有复制缺陷的。除了肿瘤溶解外,溶瘤病毒还可以诱导宿主对癌细胞的免疫反应,因此可能被视为免疫治疗的一种形式。尽管检查点抑制剂最近的成功表明增强抗肿瘤免疫是有效的,但免疫抑制肿瘤微环境的动态性为这些疗法的广泛应用带来了重大障碍。针对一种免疫抑制途径可能不足以消除肿瘤。在这里,我们专注于开发溶瘤病毒治疗与检查点抑制剂的组合,旨在靶向程序性细胞死亡蛋白1和程序性细胞死亡配体1信号轴。我们还讨论了这种新型联合疗法的临床应用的未来方向。
本文章由计算机程序翻译,如有差异,请以英文原文为准。
求助全文
约1分钟内获得全文 求助全文
来源期刊
自引率
0.00%
发文量
0
审稿时长
16 weeks
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
确定
请完成安全验证×
copy
已复制链接
快去分享给好友吧!
我知道了
右上角分享
点击右上角分享
0
联系我们:info@booksci.cn Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。 Copyright © 2023 布克学术 All rights reserved.
京ICP备2023020795号-1
ghs 京公网安备 11010802042870号
Book学术文献互助
Book学术文献互助群
群 号:481959085
Book学术官方微信